EGFR and non-small cell lung carcinoma: Somatic mutations in the epidermal growth factor receptor (EGFR) gene that activate EGFR tyrosine kinase activity are major determinants of the clinical efficacy of first-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib that are used to treat patients with non-small cell lung cancer (NSCLC) [1-5].